At the news
? NEUTRALIMPACT 2/10 8-K filed Jun 9, 2026 at 17:20 ET
Axsome Therapeutics adopted a formal Executive Severance and Change in Control Plan effective June 5, 2026, covering the CEO (Tier 1), other Section 16 officers (Tier 2), and VPs+ (Tier 3). The plan provides cash severance of 18/12/6 months' base salary outside a change of control, and 24/18/9 months' salary plus target bonus, full equity acceleration, and COBRA payments upon a qualifying termination during a change of control period. This is a routine adoption of a standardized severance framework that supersedes prior individual agreements, with no departure or appointment of any officer.
- Plan adopted June 5, 2026, approved by Compensation Committee
- CEO (Tier 1) gets 18 months base salary severance outside CIC, 24 months plus target bonus and full equity vesting during CIC period
- Other Section 16 officers (Tier 2) get 12 months base salary outside CIC, 18 months plus target bonus and full equity vesting during CIC period
- VPs+ (Tier 3) get 6 months base salary outside CIC, 9 months plus target bonus and full equity vesting during CIC period
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access